ArticleACR open rheumatology2025
Trends in Systemic Lupus Erythematous Mortality in the United States, 1999-2022.
Article in ACR open rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- National trends in hospitalisation, in-hospital mortality and resource use for SLE in Spain from 2016 to 2022.Lupus science & medicine · 2026Article
- Systemic Lupus Erythematosus Mortality Among Decedents Aged ≥15 Years-United States, 2018-2023.Arthritis care & research · 2026Article
- Phase Ib, multicentre, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneously administered mosunetuzumab in participants with systemic lupus erythematosus.Lupus science & medicine · 2026Article
- Cost-Effectiveness of Early vs Delayed Belimumab Treatment for Systemic Lupus Erythematosus.JAMA network open · 2026Article
- Systemic lupus erythematosus-related mortality declined but disparities persisted in the United States: a nationwide multiple-cause-of-death analysis, 1999-2023.Frontiers in immunology · 2026Observational
- Trends and differences in cardiovascular disease and alzheimer's disease-related mortality among older adults in the United States, 1999 to 2023: A CDC WONDER database analysis.American heart journal plus : cardiology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveSystemic lupus erythematosus (SLE) is a chronic autoimmune disease with variable mortality rates among different demographic groups. Despite treatment advancements, disparities in SLE outcomes continue to exist.
methodsThis study used the Centers for Disease Control and Prevention Wide-ranging Online Data for Epidemiologic Research database data from 1999 to 2022 to examine SLE-related mortality trends. Age-adjusted mortality rates (AAMRs) were calculated, and Joinpoint regression was employed to evaluate annual percentage changes (APCs) over time for mortality stratified by gender, race, census regions, age groups, and states.
resultsA total of 52,430 SLE-related deaths occurred over the study period. The AAMR decreased from 1 per 100,000 in 1999 to 0.78 per 100,000 in 2022. The AAMR of SLE-related deaths decreased by 21% from 1 in 1999 to 0.79 in 2019 (average APC -1.23, 95% confidence interval -1.48 to -0.96). It increased by 21.52% from 0.79 in 2019 to 0.96 in 2021. From 1999 to 2019, men decreased by 33.33% compared to 21.02% in women, whereas women saw a more considerable increase from 2019 to 2021. Non-Hispanic Asians or Pacific Islander patients saw the most decrease (-43.37%), followed by Hispanic patients (-40.60%), non-Hispanic African American patients (-25.83%), and non-Hispanic White patients (-21.43%). Hispanic patients saw the most significant increase from 2019 to 2021, whereas non-Hispanic African American patients had the highest AAMR among all racial and ethnic subgroups from 1999 to 2022. The South had the highest AAMR throughout the study period among census regions.
conclusionPersistent disparities have been observed in SLE-related mortality rates from 1999 to 2022, with female sex, non-Hispanic African American race, and southern region being disproportionately impacted by worse mortality outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.